{"DataElement":{"publicId":"3225736","version":"1","preferredName":"Embolization Therapy Agent Administered Name","preferredDefinition":"Text term to represent the name of the drug used specifically for chemoembolization in the embolization therapy.","longName":"3225728v1.0:3225732v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3225728","version":"1","preferredName":"Embolization Therapy Agent Administered","preferredDefinition":"(EM-bo-lih-ZAY-shun) The blocking of an artery by a clot or foreign material. Embolization can be done as treatment to block the flow of blood to a tumor._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)_Given.","longName":"3225726v1.0:2233610v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3225726","version":"1","preferredName":"Embolization Therapy Agent","preferredDefinition":"(EM-bo-lih-ZAY-shun) The blocking of an artery by a clot or foreign material. Embolization can be done as treatment to block the flow of blood to a tumor.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C15230:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Embolization Therapy","conceptCode":"C15230","definition":"A procedure in which substances are injected into blood vessels adjacent to a tumor for the purpose of interrupting the blood flow to the cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A041C582-8E17-4C49-E040-BB89AD434307","latestVersionIndicator":"Yes","beginDate":"2011-04-06","endDate":null,"createdBy":"WHITES","dateCreated":"2011-04-06","modifiedBy":"ONEDATA","dateModified":"2011-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A041C582-8E25-4C49-E040-BB89AD434307","latestVersionIndicator":"Yes","beginDate":"2011-04-06","endDate":null,"createdBy":"WHITES","dateCreated":"2011-04-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Curated for The Cancer Genome Atlas (TCGA) by request of T.Lichtenberg sw 4/2011 Released per TCGA approval. mc 6/30/11","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3225732","version":"1","preferredName":"Embolization Agent Name","preferredDefinition":"(EM-bo-lih-ZAY-shun) The blocking of an artery by a clot or foreign material. Embolization can be done as treatment to block the flow of blood to a tumor._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)_The words or language units by which a thing is known.","longName":"3225732v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"35","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Doxorubicin Drug Eluting Beads","valueDescription":"Doxorubicin-Eluting Beads","ValueMeaning":{"publicId":"3225734","version":"1","preferredName":"Doxorubicin-Eluting Beads","longName":"3225734","preferredDefinition":"A drug-device combination product consisting of small polymeric beads impregnated with the anthracycline antibiotic doxorubicin with potential antineoplastic activity. The beads consist of polyvinyl alcohol (PVA) microspheres modified with sulfonic acid groups and loaded with doxorubicin. During transarterial chemoembolization (TACE), doxorubicin-eluting beads embolize to the tumor vasculature and release cytotoxic doxorubicin, which may result in both ischemic necrosis of tumor tissue due to mechanical blockage of the tumor vasculature and doxorubicin-mediated inhibition of tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin-Eluting Beads","conceptCode":"C82419","definition":"A drug-device combination product consisting of small polymeric beads impregnated with the anthracycline antibiotic doxorubicin with potential antineoplastic activity. The beads consist of polyvinyl alcohol (PVA) microspheres modified with sulfonic acid groups and loaded with doxorubicin. During transarterial chemoembolization (TACE), doxorubicin-eluting beads embolize to the tumor vasculature and release cytotoxic doxorubicin, which may result in both ischemic necrosis of tumor tissue due to mechanical blockage of the tumor vasculature and doxorubicin-mediated inhibition of tumor cell proliferation.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A041C582-8E66-4C49-E040-BB89AD434307","latestVersionIndicator":"Yes","beginDate":"2011-04-06","endDate":null,"createdBy":"WHITES","dateCreated":"2011-04-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A041C582-8E7F-4C49-E040-BB89AD434307","beginDate":"2011-04-06","endDate":null,"createdBy":"WHITES","dateCreated":"2011-04-06","modifiedBy":"ONEDATA","dateModified":"2011-04-06","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2946060","version":"1","preferredName":"Other","longName":"2946060","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"746A8063-D650-3C9D-E040-BB89AD437A9B","latestVersionIndicator":"Yes","beginDate":"2009-09-25","endDate":null,"createdBy":"AHMEDS","dateCreated":"2009-09-25","modifiedBy":"GDEEN","dateModified":"2024-01-19","changeDescription":null,"administrativeNotes":"1/25/23 added alt name for ticket number CADSR0001948 for CCTG cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A041C582-8E89-4C49-E040-BB89AD434307","beginDate":"2011-04-06","endDate":null,"createdBy":"WHITES","dateCreated":"2011-04-06","modifiedBy":"ONEDATA","dateModified":"2011-04-06","deletedIndicator":"No"},{"value":"Cisplatin","valueDescription":"Cisplatin","ValueMeaning":{"publicId":"3225735","version":"1","preferredName":"Cisplatin","longName":"3225735","preferredDefinition":"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A041C582-8E93-4C49-E040-BB89AD434307","latestVersionIndicator":"Yes","beginDate":"2011-04-06","endDate":null,"createdBy":"WHITES","dateCreated":"2011-04-06","modifiedBy":"CLOHNES","dateModified":"2022-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A041C582-8EAB-4C49-E040-BB89AD434307","beginDate":"2011-04-06","endDate":null,"createdBy":"WHITES","dateCreated":"2011-04-06","modifiedBy":"ONEDATA","dateModified":"2011-04-06","deletedIndicator":"No"},{"value":"Mitomycin C","valueDescription":"Mitomycin C","ValueMeaning":{"publicId":"3202964","version":"1","preferredName":"Mitomycin C","longName":"3202964","preferredDefinition":"A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species.  Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitomycin","conceptCode":"C1820","definition":"A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species.  Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E727F7D-AEE0-154D-E040-BB89AD4315DA","latestVersionIndicator":"Yes","beginDate":"2011-03-14","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2011-03-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A041C582-8EB5-4C49-E040-BB89AD434307","beginDate":"2011-04-06","endDate":null,"createdBy":"WHITES","dateCreated":"2011-04-06","modifiedBy":"ONEDATA","dateModified":"2011-04-06","deletedIndicator":"No"},{"value":"Doxorubicin","valueDescription":"Doxorubicin","ValueMeaning":{"publicId":"2744954","version":"1","preferredName":"Doxorubicin","longName":"2744954","preferredDefinition":"An anthracycline antineoplastic antibiotic isolated from the fungus Streptococcus peucetius var. caesius.  Doxorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.  The hydrochloride salt doxorubicin hydrochloride is the therapeutic form of doxorubicin. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BB4171E-8077-21EC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A041C582-8EBF-4C49-E040-BB89AD434307","beginDate":"2011-04-06","endDate":null,"createdBy":"WHITES","dateCreated":"2011-04-06","modifiedBy":"ONEDATA","dateModified":"2011-04-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3225731","version":"1","preferredName":"Embolization Therapy Agent Name","preferredDefinition":"(EM-bo-lih-ZAY-shun) The blocking of an artery by a clot or foreign material. Embolization can be done as treatment to block the flow of blood to a tumor.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI):The words or language units by which a thing is known.","longName":"C15230:C1708:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Embolization Therapy","conceptCode":"C15230","definition":"A procedure in which substances are injected into blood vessels adjacent to a tumor for the purpose of interrupting the blood flow to the cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A041C582-8E3B-4C49-E040-BB89AD434307","latestVersionIndicator":"Yes","beginDate":"2011-04-06","endDate":null,"createdBy":"WHITES","dateCreated":"2011-04-06","modifiedBy":"ONEDATA","dateModified":"2011-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A041C582-8E4C-4C49-E040-BB89AD434307","latestVersionIndicator":"Yes","beginDate":"2011-04-06","endDate":null,"createdBy":"WHITES","dateCreated":"2011-04-06","modifiedBy":"COOPERM","dateModified":"2011-06-30","changeDescription":"Curated for The Cancer Genome Atlas (TCGA) by request of T.Lichtenberg sw 4/2011 Released per TCGA approval. mc 6/30/11","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2756809","version":"1","longName":"TCGA (The Cancer Genome Atlas)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6044923","version":"1","longName":"Active CDEs as of March 2017","context":"NCIP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"TCGA Comment","type":"COMMENT","description":"Check all that apply","url":null,"context":"NCIP"},{"name":"Drug Name","type":"Preferred Question Text","description":"Drug Name","url":null,"context":"NCIP"}],"origin":"TCGA:The Cancer Genome Atlas","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A041C582-8EC9-4C49-E040-BB89AD434307","latestVersionIndicator":"Yes","beginDate":"2011-04-06","endDate":null,"createdBy":"WHITES","dateCreated":"2011-04-06","modifiedBy":"TSESU","dateModified":"2018-07-13","changeDescription":"Curated for The Cancer Genome Atlas (TCGA) by request of T.Lichtenberg 4/2011 Modified to add new question text and definition per Misc 6.0 request. mc 6/22/11 Released per approval from Tara. mc 6/30/11","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}